Literature DB >> 22231875

Pathology of endometrioid carcinoma.

Anne-Flore Albertini1, Mojgan Devouassoux-Shisheboran, Catherine Genestie.   

Abstract

Endometrioid carcinoma is the third most frequent cancer among women in France. They are divided in two groups: type I and type II. This article describes anatomopathological and molecular features of this disease. Type I carcinoma, the most frequent, develops in a context of hyperoestrogenia. Endometrial glandular hyperplasia is the precursor lesion. The histological type is an endometrioid carcinoma. Its prognosis is good. Type II carcinoma is less frequent. It occurs on an atrophic mucosa. It is usually a more aggressive tumor like serous adenocarcinoma, clear cells carcinoma or carcinosarcoma with a poor prognosis. Type I and type II carcinoma also present different molecular pathways. PTEN inactivation, an early event in carcinogenesis, is the most frequent abnormality in type I carcinoma. An average of 28% of type I carcinoma also acquire PI3K mutations. On the contrary, P53 mutation is involved in 90% of type II carcinoma. Identifying and understanding these two types of endometrial carcinoma led to various therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231875     DOI: 10.1684/bdc.2011.1526

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  9 in total

1.  Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities.

Authors:  Alessandro Rizzo
Journal:  J Clin Med       Date:  2022-07-05       Impact factor: 4.964

2.  Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.

Authors:  Nan Jia; Qing Li; Xiang Tao; Jieyu Wang; Keqin Hua; Weiwei Feng
Journal:  Oncol Lett       Date:  2014-08-12       Impact factor: 2.967

3.  Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.

Authors:  Pierre Alain Reboux; Henri Azaïs; Charles Henry Canova; Sofiane Bendifallah; Lobna Ouldamer; Emilie Raimond; Delphine Hudry; Charles Coutant; Olivier Graesslin; Cyril Touboul; Pierre Collinet; Alexandre Bricou; Cyrille Huchon; Emile Daraï; Marcos Ballester; Jean Lévêque; Vincent Lavoué; Martin Koskas; Catherine Uzan; Geoffroy Canlorbe
Journal:  J Gynecol Oncol       Date:  2019-02-07       Impact factor: 4.401

4.  Predicting prognosis of endometrioid endometrial adenocarcinoma on the basis of gene expression and clinical features using Random Forest.

Authors:  Fufen Yin; Xingyang Shao; Lijun Zhao; Xiaoping Li; Jingyi Zhou; Yuan Cheng; Xiangjun He; Shu Lei; Jiangeng Li; Jianliu Wang
Journal:  Oncol Lett       Date:  2019-06-20       Impact factor: 2.967

Review 5.  Progesterone Actions and Resistance in Gynecological Disorders.

Authors:  James A MacLean; Kanako Hayashi
Journal:  Cells       Date:  2022-02-13       Impact factor: 6.600

6.  Preliminary Application of Magnetization Transfer Imaging in the Study of Normal Uterus and Uterine Lesions.

Authors:  Qiu Bi; Qing Li; Jing Yang; Junyu Yang; Ji Du; Fan Ding; Yunzhu Wu; Shaoyu Wang; Ying Zhao
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

7.  Construction of a miRNA-Based Nomogram Model to Predict the Prognosis of Endometrial Cancer.

Authors:  Leyi Ni; Chengyun Tang; Yuning Wang; Jiaming Wan; Morgan G Charles; Zilong Zhang; Chen Li; Ruijie Zeng; Yiyao Jin; Penghao Song; Ming Wei; Bocen Li; Jin Zhang; Zhenghao Wu
Journal:  J Pers Med       Date:  2022-07-17

8.  Coexistence of malignant ovarian Brenner tumor and borderline mucinous cystadenoma, combined with primary uterine corpus endometrioid carcinoma: A case report and literature review.

Authors:  Cancan Zou; Qiong Li; Jingbo Zhao; Yanlin Chen
Journal:  Oncol Lett       Date:  2022-06-22       Impact factor: 3.111

9.  Involvements of Estrogen Receptor, Proliferating Cell Nuclear Antigen and p53 in Endometrial Adenocarcinoma Development in Donryu Rats.

Authors:  Midori Yoshida; Shin-Ichi Katsuda; Akihiko Maekawa
Journal:  J Toxicol Pathol       Date:  2012-12-20       Impact factor: 1.628

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.